Cite
Correction to: Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicenter Spanish study.
MLA
Garcia-Romero, Ruth, et al. “Correction to: Safety and Effectiveness of Vedolizumab in Paediatric Patients with Inflammatory Bowel Disease: An Observational Multicenter Spanish Study.” European Journal of Pediatrics, vol. 180, no. 9, Sept. 2021, pp. 3039–40. EBSCOhost, https://doi.org/10.1007/s00431-021-04117-9.
APA
Garcia-Romero, R., de Zabarte Fernandez, J. M. M., Pujol-Muncunill, G., Donat-Aliaga, E., Segarra-Cantón, O., Irastorza-Terradillos, I., Medina-Benitez, E., Ruiz-Hernández, C. J., Carrillo-Palau, M., Ros-Arnal, I., Rodriguez-Martínez, A., Escartin-Madurga, L., Gutiérrez-Junquera, C., Vicente-Santamaría, S., Rodriguez-Belvis, M. V., Fernández-Fernández, S., Alberto-Alonso, J. R., Montraveta, M., Torres-Peral, R., & Navalon-Rubio, M. (2021). Correction to: Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicenter Spanish study. European Journal of Pediatrics, 180(9), 3039–3040. https://doi.org/10.1007/s00431-021-04117-9
Chicago
Garcia-Romero, Ruth, José Miguel Martinez de Zabarte Fernandez, Gemma Pujol-Muncunill, Ester Donat-Aliaga, Oscar Segarra-Cantón, Iñaki Irastorza-Terradillos, Enrique Medina-Benitez, et al. 2021. “Correction to: Safety and Effectiveness of Vedolizumab in Paediatric Patients with Inflammatory Bowel Disease: An Observational Multicenter Spanish Study.” European Journal of Pediatrics 180 (9): 3039–40. doi:10.1007/s00431-021-04117-9.